# Nonmyeloablative Stem Cell Transplantation for Chronic Lymphocytic Leukemia (CLL)

> **NCT00899431** · PHASE2 · TERMINATED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 39 (actual)

## Conditions studied

- Chronic Lymphocytic Leukemia

## Interventions

- **DRUG:** Lenalidomide
- **DRUG:** Fludarabine
- **DRUG:** Rituximab
- **DRUG:** Thymoglobulin
- **PROCEDURE:** Stem Cell Transplantation
- **DRUG:** Bendamustine
- **DRUG:** Allopurinol

## Key facts

- **NCT ID:** NCT00899431
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-05-06
- **Primary completion:** 2018-10-07
- **Final completion:** 2018-10-07
- **Target enrollment:** 39 (ACTUAL)
- **Why stopped:** Terminated per PI's request at the time of continuing review
- **Last updated:** 2020-01-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00899431

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00899431, "Nonmyeloablative Stem Cell Transplantation for Chronic Lymphocytic Leukemia (CLL)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT00899431. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*